COVID vaccination in female, male partners does not increase risk of miscarriage

Nov. 22, 2023
The new study found a slightly lower risk of miscarriage among vaccinated partners trying to conceive.

A new study led by Boston University School of Public Health (BUSPH) researchers now provides deeper insight into the safety of COVID-19 vaccines for people planning to become pregnant.

Published in the journal Human Reproduction, the study found no increased risk of early or late miscarriage as a result of male or female partners getting a COVID-19 vaccine prior to conceiving.

The study is of the first to evaluate the risk of early miscarriage (less than eight weeks’ gestation) following preconception COVID-19 vaccination, as well as the first to evaluate male vaccination and miscarriage.

For the study, Jennifer Yland, an epidemiology PhD student at BUSPH at the time of the study, and colleagues analyzed survey data on COVID-19 vaccination and miscarriage among female and male participants in the BUSPH-based Pregnancy Study Online (PRESTO), an ongoing National Institutes of Health-funded study that enrolls women trying to conceive, and follows them from preconception through six months after delivery. Participants in this new analysis included 1,815 female individuals in the US and Canada who were followed in the study from December 2020 through November 2022. They were observed from their first positive pregnancy test until a miscarriage or other event (such as induced abortion, ectopic pregnancy, or 20 weeks’ gestation)—whichever occurred first.

Among the female participants, 75 percent had received at least one dose of a COVID-19 vaccine by the time they became pregnant. Almost a quarter of the pregnancies resulted in miscarriage, and 75 percent of these miscarriages occurred prior to 8 weeks’ gestation, but there was no increased risk.

Risk of miscarriage was 26.6 percent among unvaccinated female participants, 23.9 percent among female participants who had received one dose of the vaccine before conception, 24.5 percent among those who completed a full primary series before conception, 22.1 percent among those who completed the vaccine series three months before conception, and 20.1 percent among those who received only one dose of a two-dose vaccine before conception.

Boston University School of Public Health release on Newswise